long intergenic non-protein coding RNA 945Genealiases: []
Q-omics provides the consensus-scored LINC00945 profile across patient tissues and cancer cell-line models. LINC00945 expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, LINC00945 is differentially expressed in 4, with the highest sampling consensus in KIRP. Additionally, LINC00945 RNA expression shows 8,044 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight UVM, KIRP, and TGCT as cancer lineages where LINC00945 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC00945 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC00945 survival associations across molecular data types. LINC00945 RNA expression shows survival associations in the most cancer types (18). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC00945 RNA expression–survival associations across cancer types. High LINC00945 expression shows unfavorable associations in UVM, KIRC, HNSC, CESC, BLCA and UCEC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for LINC00945 RNA expression.
This table summarizes LINC00945 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for LINC00945. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC00945 shows lower tumor expression in KIRP and higher tumor expression in BRCA, LUAD and PRAD. The KIRP box plot shows higher LINC00945 RNA expression in normal versus tumor tissue (log2 FC = −0.094, t-test p < 0.001).
This table shows molecular features associated with LINC00945 in patient tissues and cancer cell lines. In patient samples, LINC00945 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
